Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression

Autor: Jane Rogan, Sharzad Moghadam, Theodora Germetaki, M. Braun, Mark P Saunders, Antje Lukas, Eva Lenfert, Daniel L. Edelstein, Camille Nicholls, Frederick S. Jones, Richard Adams

Aim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based testing is a viable alternative. We also evaluated the change in mutation status on progression. Mat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd86098bcb9c7183b5d6c65414b80b00
https://orca.cardiff.ac.uk/id/eprint/141030/1/fon-2020-0523.pdf

Abstract 3810: Persistence of smoking signature 4 in the non-small cell lung cancer genome

Autor: Fiona H Blackhall, Helene Schlecht, Sharzad Moghadam, Andrew L. Wallace, Pantelis A. Nicola, George J Burghel, Eleanor Baker, Shereen Rafee, Jane Rogan, Colin R Lindsay, Mathew Carter, Lynsey Priest, William G. Newman, Robert G. Bristow, Katie Baker

Publikováno v: Cancer Research. 80:3810-3810

Introduction Lung cancer is the most common cause of cancer-related death. Carcinogenic and endogenous processes driving somatic mutation acquisition in cancer can be extracted and defined as mutational signatures using whole genome sequencing (WGS).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67ed7aa0a87557d01730cf322bc87e80
https://doi.org/10.1158/1538-7445.am2020-3810

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers

Autor: Catherine Billington, Alison Backen, Sharzad Moghadam, Jane Rogan, Richard A Hubner, Juan W. Valle, Salvatore Galdy, Mairéad G McNamara, Elizabeth A. H. Beckett, Angela Lamarca, Jorge Barriuso, Angela Cramer

Publikováno v: PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0206007 (2018)
Lamarca, A, Galdy, S, Barriuso, J, Moghadam, S, Beckett, E, Rogan, J, Backen, A, Billington, C, Mcnamara, M, Hubner, R, Cramer, A & Valle, J 2018, ' The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers ', P L o S One, vol. 13, no. 10, e0206007 . https://doi.org/10.1371/journal.pone.0206007

IntroductionExpression of human epidermal growth factor receptor (HER)2 and HER3 have been investigated in small BTC studies using variable scoring systems. Methods HER2 and HER3 overexpression/amplification were explored following internationally ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f476ed27f49cbd140ef458625016916
http://europepmc.org/articles/PMC6193702

HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs):A retrospective analysis

Autor: Angela Lamarca, Juan W. Valle, Sharzad Moghadam, Salvatore Galdy, Angela Cramer, Jane Rogan, Mairéad G McNamara, Richard A Hubner

Publikováno v: Lamarca, A, Galdy, S, Moghadam, S, Rogan, J, Mcnamara, M, Hubner, R, Cramer, A & Valle, J 2017, ' HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs) : A retrospective analysis ', ESMO 2017 Congress, Madrid, Spain, 8/09/17-12/09/17 . < https://doi.org/10.1093/annonc/mdx369.108 >

Background: Cholangiocarcinoma (CC), gallbladder cancer (GBC) and ampullary cancer (AC) (collectively BTCs) are poor-prognosis cancers. Cisplatin-gemcitabine chemotherapy is the standard treatment for patients (pts) with advanced BTC. New treatment t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771323a176b3201c1097f69437a634b1
https://doi.org/10.1093/annonc/mdx369.108

Abstract 1763: Tumor mutational burden, mutational signatures and copy number variation in lung cancer driven by the Ras-Raf-MEK-ERK pathway

Autor: Helene Schlecht, Fiona H Blackhall, Mathew Carter, Lynsey Priest, George J Burghel, Colin R Lindsay, Eleanor Baker, Katie Baker, Jane Rogan, Pantelis A. Nicola, William G. Newman, Robert G. Bristow, Sharzad Moghadam, Andrew L. Wallace

Publikováno v: Cancer Research. 79:1763-1763

Introduction: Lung cancer is the most common cause of cancer-related death. Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated gene in non-small cell lung cancer (NSCLC), occurring in approximately 30% of cases. We characterised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7dd2a19c44f8b97edda45177b5f3b880
https://doi.org/10.1158/1538-7445.am2019-1763